SAVER reports no contralateral nodal failures with reduced elective volumes in HPV-positive oropharyngeal cancer
Among 52 HPV-positive oropharyngeal cancer patients, SAVER observed no contralateral nodal failures at median 31 months while reducing parotid dose.